Every B12 product makes a form choice, and the two dominant options tell different chemical stories. Cyanocobalamin — the original synthetic workhorse, stabilised by a cyanide group. Methylcobalamin — one of the two coenzyme forms human enzymes actually employ. The marketing framing of this comparison is often overwrought; the honest scientific framing is more interesting, because it is a story about conversion steps, stability trade-offs, and what quality testing must verify in each case.
What the forms actually are
Cobalamin is a cobalt atom held in a corrin ring; the “form” is simply whichever chemical group occupies the cobalt’s upper coordination position. In cyanocobalamin it is a cyano group (–CN) — not found in food in meaningful amounts, but conferring exceptional chemical stability, which is why industrial synthesis standardised on it in the 1950s and why most fortified foods and older trials used it. In methylcobalamin it is a methyl group: this is the coenzyme of methionine synthase, the cytoplasmic enzyme that recycles homocysteine to methionine and feeds the body’s methylation economy. (Its sibling, adenosylcobalamin, serves the mitochondrial enzyme methylmalonyl-CoA mutase; food and plasma B12 is predominantly methyl- and adenosyl-.) The crucial biochemical footnote that deflates most marketing: whatever form you swallow, cells strip the upper group and rebuild the coenzyme forms themselves. Cyanocobalamin must first be decyanated (releasing a toxicologically trivial trace of cyanide — micrograms, far below any concern threshold, though the step exists) and then remade into methyl/adenosyl forms; methylcobalamin arrives as a finished coenzyme but is still processed through the same intracellular machinery.
What the evidence honestly shows
Stated plainly, as the review literature does (Obeid 2015; Paul & Brady 2017): both forms correct B12 deficiency. Head-to-head clinical trials showing methylcobalamin’s superiority on hard outcomes do not exist in convincing form; cyanocobalamin has the longer trial record simply by historical accident of availability. The defensible differences are narrower and real: methylcobalamin is the physiological plasma form and skips the decyanation step — a rational preference, particularly speculated to matter in heavy smokers (whose cyanide load is already elevated) and in rare inborn errors of cobalamin metabolism, though these remain mechanistic arguments more than trial-proven ones. Some pharmacokinetic work suggests modestly different retention profiles between forms, with methylcobalamin showing favourable tissue retention in several studies — again, differences of degree, not of category. The honest summary: choose methylcobalamin for coenzyme-form directness; do not believe anyone who claims cyanocobalamin doesn’t work. Dose and route (the high-dose oral logic) matter far more than the upper ligand.
The stability trade — and why testing must match the form
Chemistry charges a price for the coenzyme form: methylcobalamin is markedly less stable than cyanocobalamin — sensitive above all to light, which cleaves the cobalt–methyl bond (the photochemistry our amber-glass article covers in full), and demanding more care with heat and formulation pH. This is a solvable engineering problem — opaque or amber packaging, appropriate formulation — but it converts quality control into a form-specific obligation. A certificate of analysis for a methylcobalamin product must verify by identity-resolving HPLC that the analyte is actually methylcobalamin, not “total cobalamins”: a degraded product’s B12 may have photolysed to hydroxocobalamin, which a non-specific assay happily counts. Form-specific identity plus degradation-product testing (see reading a CoA) is the analytical signature separating products that chose the harder form and did the work from products that chose the harder form for the label.
The clinical bottom line
Cyanocobalamin is the stable synthetic that works after a conversion step; methylcobalamin is the finished coenzyme that asks more of formulation and packaging. Trials show both correct deficiency — the form difference is about directness and physiology, not about one form failing. Pick methylcobalamin as the rational coenzyme choice, then verify the product honoured it: light-protective packaging and form-specific HPLC identity on the certificate. And as always: diagnosed deficiency is a medical condition first, a supplement decision second.
Primary sources
- Obeid R, Fedosov SN, Nexo E. Cobalamin coenzyme forms are not likely to be superior to cyano- and hydroxyl-cobalamin in prevention or treatment of cobalamin deficiency. Mol Nutr Food Res. 2015;59(7):1364–1372. doi:10.1002/mnfr.201500019
- Paul C, Brady DM. Comparative bioavailability and utilization of particular forms of B12 supplements with potential to mitigate B12-related genetic polymorphisms. Integr Med (Encinitas). 2017;16(1):42–49. PMID: 28223907
- Green R, Allen LH, Bjørke-Monsen AL, et al. Vitamin B12 deficiency. Nat Rev Dis Primers. 2017;3:17040. doi:10.1038/nrdp.2017.40
- Kuzminski AM, et al. Effective treatment of cobalamin deficiency with oral cobalamin. Blood. 1998;92(4):1191–1198. doi:10.1182/blood.V92.4.1191
- EFSA NDA Panel. Dietary Reference Values for cobalamin (vitamin B12). EFSA Journal. 2015;13(7):4150. doi:10.2903/j.efsa.2015.4150
Educational information, not medical advice. B12 deficiency diagnosis and treatment decisions belong with your physician.
Was this article helpful?
Related Coverage
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
